方盛制药
(603998)
| 流通市值：54.45亿 | | | 总市值：54.45亿 |
| 流通股本：4.39亿 | | | 总股本：4.39亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 834,248,975.63 | 418,083,503.37 | 1,777,494,393.87 | 1,347,963,171.04 |
| 营业收入 | 834,248,975.63 | 418,083,503.37 | 1,777,494,393.87 | 1,347,963,171.04 |
| 二、营业总成本 | 683,068,914.91 | 340,146,773.39 | 1,531,784,897.55 | 1,150,514,693.55 |
| 营业成本 | 247,790,990.68 | 123,326,150.06 | 500,368,336.15 | 365,894,825.75 |
| 税金及附加 | 16,069,167.7 | 8,073,005.35 | 30,981,768.79 | 23,255,167.5 |
| 销售费用 | 280,128,148.16 | 141,018,818.65 | 702,914,018.48 | 547,605,801.46 |
| 管理费用 | 64,926,056.81 | 32,547,234.78 | 145,849,448.13 | 103,654,774.8 |
| 研发费用 | 68,088,518.71 | 31,879,608.54 | 139,214,230.43 | 103,389,362.79 |
| 财务费用 | 6,066,032.85 | 3,301,956.01 | 12,457,095.57 | 6,714,761.25 |
| 其中:利息费用 | 8,158,700.25 | 4,467,680.52 | 21,785,269.86 | 16,169,150.16 |
| 其中:利息收入 | 2,285,280.76 | 1,282,843.79 | 9,660,242.2 | 10,307,904.55 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -21,182.07 | 50,538.34 |
| 加:投资收益 | 1,376,986.92 | -812,038.81 | 38,557,369.89 | 41,981,598.41 |
| 资产处置收益 | 20,660,730.85 | 15,272,816.18 | 746,351.63 | 790,928.47 |
| 资产减值损失(新) | -54,625.6 | 376,880.9 | -20,619,446.54 | -2,092,763.64 |
| 信用减值损失(新) | 4,220,282.52 | 2,864,893.35 | -5,184,775.58 | -12,309,747.32 |
| 其他收益 | 9,729,191.43 | 3,665,909.9 | 26,156,471.26 | 23,146,797.38 |
| 四、营业利润 | 187,112,626.84 | 99,305,191.5 | 285,344,284.91 | 249,015,829.13 |
| 加:营业外收入 | 147,055.43 | 85,474.56 | 1,278,749.98 | 1,386,370.77 |
| 减:营业外支出 | 766,371.56 | 222,345.92 | 635,493.2 | 422,169.97 |
| 五、利润总额 | 186,493,310.71 | 99,168,320.14 | 285,987,541.69 | 249,980,029.93 |
| 减:所得税费用 | 19,999,230.49 | 10,443,818.42 | 36,138,675.25 | 22,583,288.74 |
| 六、净利润 | 166,494,080.22 | 88,724,501.72 | 249,848,866.44 | 227,396,741.19 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 166,494,080.22 | 88,724,501.72 | 249,848,866.44 | 227,396,741.19 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 169,238,666.58 | 88,257,931.44 | 255,216,208.09 | 228,138,496.75 |
| 少数股东损益 | -2,744,586.36 | 466,570.28 | -5,367,341.65 | -741,755.56 |
| 扣除非经常损益后的净利润 | 141,471,405.86 | 70,827,987.91 | 193,089,411.89 | 162,919,995.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.39 | 0.2 | 0.59 | 0.53 |
| (二)稀释每股收益 | 0.39 | 0.2 | 0.58 | 0.52 |
| 九、综合收益总额 | 166,494,080.22 | 88,724,501.72 | 249,848,866.44 | 227,396,741.19 |
| 归属于母公司股东的综合收益总额 | 169,238,666.58 | 88,257,931.44 | 255,216,208.09 | 228,138,496.75 |
| 归属于少数股东的综合收益总额 | -2,744,586.36 | 466,570.28 | -5,367,341.65 | -741,755.56 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-29 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |